Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1/2 2Phase 4 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 2Tumor-Agnostic 1NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 10lutetium Lu 177 dotatate 7Magnetic Resonance Spectroscopy 7pasireotide 4Specimen Handling 3Positron Emission Tomography Computed Tomography 3Nivolumab 3Ga(III)-DOTATOC 3Fluorodeoxyglucose F18 3(177)Lu-DOTA-EB-TATE 3olaparib 2gallium Ga 68 dotatate 2amino-acid, glucose, and electrolyte solution 2Temozolomide 2Lutetium-177 2Ipilimumab 2FAPI-46 2veliparib 1vandetanib 1trifluridine tipiracil drug combination 1toripalimab 1tislelizumab 1talazoparib 1surufatinib 1romidepsin 1peposertib 1pembrolizumab 1pelcitoclax 1pegfilgrastim 1lanreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × surufatinib × NET × Clear all
NCT02267967 2018-11-13

Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors

Hutchmed

Phase 1 Completed
81 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡